GlassScriptPhysician profile
Claudia C Gammon
NPI 1063523074
$1,808.69
in general payments reported to CMS, 2019-2025
23 companies · $1,254 in 2025
The $1,254 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $71.47 · 2022: $17.24 · 2023: $132 · 2024: $335 · 2025: $1,254.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,720.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,719.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $405.69 | 2023-2025 | Inspire |
| Axsome Therapeutics, INC. | $268.80 | 2023-2025 | Sunosi |
| Grifols USA, LLC | $134.88 | 2025 | Prolastin-C Liquid |
| Baxter Healthcare | $132.43 | 2025 | Hillrom - Vest System Model 105 Home Care |
| Insmed, INC. | $116.82 | 2025 | Brinsupri, Arikayce |
| Harmony Biosciences LLC | $103.51 | 2023-2025 | Wakix |
| Astrazeneca Pharmaceuticals LP | $83.52 | 2025 | Tezspire, Fasenra |
| Actelion Pharmaceuticals US, INC. | $73.37 | 2025 | Opsumit, Uptravi, Opsynvi |
| United Therapeutics Corporation | $55.62 | 2025 | Tyvaso |
| Idorsia Pharmaceuticals US INC | $50.78 | 2024-2025 | Quviviq, Quviviq |
| Genzyme Corporation | $48.83 | 2025 | |
| Verona Pharma, INC. | $48.09 | 2025 | Ohtuvayre |
| Glaxosmithkline, LLC. | $45.44 | 2025 | Trelegy Ellipta, Nucala |
| Merck Sharp & Dohme LLC | $42.53 | 2022-2025 | Keytruda |
| Fisher & Paykel Healthcare INC | $38.65 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.17 | 2025 | Ofev |
| Electromed, INC. | $23.15 | 2025 | Smartvest |
| Jazz Pharmaceuticals INC. | $21.02 | 2021 | |
| Philips North America LLC | $18.85 | 2024 | (7999) Src Und |
| Regeneron Healthcare Solutions, INC. | $18.67 | 2025 | Dupixent |
| Viatris Specialty LLC | $15.79 | 2025 | Yupelri |
| Lilly USA, LLC | $15.28 | 2025 | Zepbound |
| Eisai INC. | $11.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Claudia Gammon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.